A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2006
10/26/2006	US20060241112 Kinase inhibitors
10/26/2006	US20060241096 Agent for preventing or treating organ functional disorders and organ dysfunction
10/26/2006	US20060241085 Compounds having anti-proliferative properties
10/26/2006	US20060241054 Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
10/26/2006	US20060241051 Metastin derivatives and use thereof
10/26/2006	US20060241049 below the kneecap in a diabetic subject; administering agonist of the non-proteolytically activated thrombin receptor
10/26/2006	US20060241035 Use of dg153 secreted protein products for preventing and treating pancreatic disease and/or obesity and/or metabolic syndrome
10/26/2006	US20060241019 Long lasting insulin derivatives and methods thereof
10/26/2006	US20060240166 Modified acacia and use thereof
10/26/2006	US20060240120 Composition for lowering blood glucose
10/26/2006	US20060240095 Pharmaceutical composition comprising a combination of metformin and a statin
10/26/2006	US20060240023 Apoptosis-associated protein and use thereof
10/26/2006	US20060240019 Antagonists of HMG1 for treating inflammatory conditions
10/26/2006	US20060240015 Recombinant antibody against human insulin-like growth factor
10/26/2006	US20060239990 Protein Arginine N-Methyltransferase 2 (PRMT-2)
10/26/2006	US20060239959 Method for treating hypercholesterolemia with polyallylamine polymers
10/26/2006	DE4244539B4 Duale Inhibitoren der No-Synthese und Cyclooxygenase, Verfahren zu ihrer Herstellung und therapeutische Präparate, die sie enthalten Dual inhibitors of NO synthesis and cyclooxygenase, processes for their preparation and therapeutic compositions containing them
10/26/2006	DE102005019094A1 New aza-heterocyclic compounds are tyrosine kinase inhibitor useful to prevent and/or treat cancer, tumor growth, tumor angiogenesis, arteriosclerosis, diabetic retinopathy and inflammation diseases
10/26/2006	DE102005018389A1 Azolderivate als Inhibitoren von Lipasen und Phospholipasen Azole derivatives as inhibitors of lipases and phospholipases
10/26/2006	CA2675652A1 Dosage forms of risedronate
10/26/2006	CA2606301A1 Azole derivatives in the form of lipase and phospholipase inhibitors
10/26/2006	CA2605778A1 Fused heterocyclic compound
10/26/2006	CA2605421A1 Functions and uses of gpr39 gene in central nervous system in mammals
10/26/2006	CA2604719A1 Substituted 2-amin0alkylthi0-benzimidaz0les and use thereof for reducing blood sugar levels
10/25/2006	EP1714981A2 Method for the identification of antigenic peptides
10/25/2006	EP1714673A1 Method for lengthening the mobility period of fish
10/25/2006	EP1714652A2 Use of thiazolidinediones to prevent or delay onset of niddm
10/25/2006	EP1714648A1 Combination drug
10/25/2006	EP1713804A1 Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
10/25/2006	EP1713803A1 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
10/25/2006	EP1713779A1 Indazole derivatives as inhibitors of hormone-sensitive lipases
10/25/2006	EP1713499A1 Methods and compounds for modulating triglyceride and vldl secretion
10/25/2006	EP1713480A2 The use of quaternary pyridinium salts as vasoprotective agents
10/25/2006	EP1713447A1 Particulate plant sterol compositions
10/25/2006	EP1517909B1 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
10/25/2006	EP1509498B1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
10/25/2006	EP1458718B1 Quinolinones as prostaglandin receptor ligands
10/25/2006	EP1430053B1 AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN
10/25/2006	EP1383511B1 Calcilytic compounds
10/25/2006	EP1331938B1 Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome
10/25/2006	EP1315721B1 A thiazolidinedione derivative and its use as antidiabetic
10/25/2006	EP1265606B1 Cell adhesion inhibitors
10/25/2006	EP1129112B1 Peptides containing a cholesterol recognition sequence and their uses
10/25/2006	EP1079811B1 Biodegradable sustained-release alginate gels
10/25/2006	EP0827408B1 Method of administration of igf-i
10/25/2006	CN1852911A Epimeridinoside A and epimeredi indica root extract preparation containing same and preparing method therefor
10/25/2006	CN1852907A 2-amino-5-benzoylthiazole npy antagonists
10/25/2006	CN1852904A Endurance improving agent
10/25/2006	CN1852899A Polymorphic forms of a known antihyperlipemic agent
10/25/2006	CN1852894A Crystalline forms of [R-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
10/25/2006	CN1852731A Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
10/25/2006	CN1852720A Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
10/25/2006	CN1852719A Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
10/25/2006	CN1852718A 2-alkylidene-19-nor-vitamin D derivatives for the treatment of frailty, muscle damage or sarcopenia
10/25/2006	CN1852717A 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
10/25/2006	CN1852716A Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
10/25/2006	CN1852709A Macrophage activation inhibitor
10/25/2006	CN1850851A Method for preparing total saponins from theroots of platycodon grandiflorum utilizing weak polarity macroreticular resin and its use
10/25/2006	CN1850850A 17a-oxa-D-carburated 5 alpha-androstane-17-one-3beta-alcohol ester, and its preparing method and use
10/25/2006	CN1850841A 5 alpha-androstane-17-one-3beta alcohol ester, and its preparing method and use
10/25/2006	CN1850840A 2-oxa-5 alpha-androstane-3-one-17 alcohol ester, and its preparing method and use
10/25/2006	CN1850836A Celosia argentea suponin compound and its pharmaceutical use
10/25/2006	CN1850242A Compounded mongolia medicine for treating diabetes and preparing method
10/25/2006	CN1850215A Pollen-Typhae tablet Chinese medicinal formula and method for preparing tablets thereof
10/25/2006	CN1850214A Method for identifying effective components of pollen Typhae tablet and content thereof
10/25/2006	CN1850212A Valerianoil liquid hard capsule, and its preparing method
10/25/2006	CN1850177A Method for preparing micropill capsule of salvia miltiorrhiza bge, and gynostemma pentaphyllum, and its use
10/25/2006	CN1850167A Thirsty-relieving blood-sugar-reducing dropping pills and preparing method
10/25/2006	CN1850166A Composition of white mulberry leaf blood-sugar-reducing effective components and preparing method
10/25/2006	CN1850164A Chinese medicine preparation for maintaining internal environment balance of humanbody
10/25/2006	CN1850127A Soft capsule of forest frogoil, royal jelly and seed kernel oil of pinus pumila reg, and its preparing process
10/25/2006	CN1850126A Propolis ganoderma lucidum spore, dried black fungus polysaccharide compounded soft capsule and preparing process therefor
10/25/2006	CN1850123A Method for preparing humanbody nutritious intensifier preparation by using winter mushroom and use
10/25/2006	CN1850112A Polyethylene glycol electrolyte oral solution
10/25/2006	CN1850106A Pharmaceutical use of polymannuronic acid sulfate for preventing and trenting diabetes
10/25/2006	CN1850093A Stibene-glucoside oral liquid and its production method
10/25/2006	CN1850092A Pharmaceutical use of guluronic acid oligose sulfate for preventing and treating diabetes
10/25/2006	CN1850091A Pharmaceutical use of alginate oligose sulfate for preventing and treating diabetes
10/25/2006	CN1850069A Method for preparing Tengchasu dispersibletablet and its use
10/25/2006	CN1850063A Composition containing fibrate drug and taurine
10/25/2006	CN1281608C New azo-indolyl derivatives
10/25/2006	CN1281604C Substituted pyrazole compounds
10/25/2006	CN1281598C Compounds and methods for modulation of estrogen receptors
10/25/2006	CN1281255C Medication for treating ulcer of lower limb of patients of skin disease and diabetic, and preparation method
10/25/2006	CN1281240C Medicinal composition for preventing and treating cardiovascular heart disease and its preparation
10/25/2006	CN1281225C Health-care food for diabetes mellitus patient
10/25/2006	CN1281217C Use of activated carbon in oral medicinal preparation for hyperthyroidism
10/25/2006	CN1281216C Instant nutrition intensifying agent
10/25/2006	CN1281158C Extraction of water soluble organic calcium from egg shell of birds and preparation of two-calcium nutrient intensifying liguor
10/25/2006	CN1281141C Health edible oil
10/24/2006	US7126012 Has affinity for melatonin receptors and/or selectivity for melatoninergic receptors; antiinflammatory and anticarcinogic agents
10/24/2006	US7126004 Thiazoline acid derivatives
10/24/2006	US7125990 For treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms
10/24/2006	US7125979 Upstream control elements of the proopiomelanocortin gene and their use
10/24/2006	US7125906 Indole derivatives having anti-angiogenetic activity
10/24/2006	US7125905 Pyrrole substituted 2-indolinone protein kinase inhibitors
10/24/2006	US7125900 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
10/24/2006	US7125898 Kinase inhibitors to mediate disease and as antiinflammatory agents
10/24/2006	US7125897 Slowing or arresting progression of plaque in blood systems treatment with statins and oxidation
10/24/2006	US7125891 Such as (1-((2,3-dihydro-2-(4-propyl-1H-imidazol-2-yl)-1H-indol-1 -yl)carbonyl)propyl)-carbamate; for inactivation of cholecystokinins

1 ... 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 ... 1298